AskBio answers investors’ call

Why AskBio finally took venture money to invest in its own gene therapy pipeline

Since 2001, gene therapy company Asklepios has subsisted chiefly on cash from licensing deals or transaction fees on programs sold off to biopharmas. Now, with $225 million in new series A funding from TPG Capital and Vida Ventures -- plus another $10 million from board members and company management -- the company is seeking to control its own pipeline and develop its

Read the full 626 word article

User Sign In